Histone Deacetylase Inhibitors

All categories
DBCAT001486Therapeutic category

Compounds that inhibit HISTONE DEACETYLASES. This class of drugs may influence gene expression by increasing the level of acetylated HISTONES in specific CHROMATIN domains. A DrugBank category of 27 drugs. 7 of them are approved.

Part of
Antineoplastic Agents
Also known as
Antineoplastic histone deacetylase (HDAC) inhibitors · Deacetylase Inhibitor, Histone · Deacetylase Inhibitors, Histone · HDAC Inhibitors · Histone Deacetylase Inhibitor
Drugs

and 2 more with a free account

What you can answer from here — as of May 26, 2021

27DrugsEach linked to its full drug card
Sign in
39Drug targetsEvery drug–target pair in the class, with bond type
Sign in
1,228Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
4Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Histone Deacetylase Inhibitors share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In